Hear how the Program of Glyco-Immunology and Oncology (PGIO) is deciphering cancer’s ‘glyco code’ to pave the way for more precise diagnostics and next generation immunotherapies
Acquisition strengthens Roche’s digital pathology and companion diagnostic portfolio to advance precision medicine
New Sprint, Flex, and Flex+ packages deliver faster turnaround times, expanded vector options, and advanced codon optimization through a modern digital ordering experience
Expanded portfolio enables flexible panel design for flow cytometry and fluorescent western blot applications
New research‑use platform combines MSC cells and culture media to support immunology and regenerative medicine workflows
Explore advances in lab testing methods moving food allergy diagnosis beyond skin pricks and into molecular precision
Collaboration integrates LucentAD Complete into AI‑driven clinical workflows to support earlier detection and treatment decisions
Due to remarkable advances in genetic sequencing technology, researchers now have an abundance of tools at their disposal. From first-generation Sanger sequencing to next-generation or massively parallel sequencing, your choice of technique and technology must first and foremost complement your chosen application and help answer your specific research questions.
Approval by Japan’s MHLW enables use of MyChoice Test as a companion diagnostic for Lynparza in prostate cancer
Certification reaffirms assay results are aligned with specialized mass spectrometry testing method
Last chance to vote for the products that have made the most difference to your research and be in with a chance to win a $100 Amazon Gift Card (or equivalent currency)
Compact, user‑friendly titrator delivers reliable accuracy for quality control laboratories
New Gibco™ CTS™ DynaXS™ single use bioreactor platform enables controlled, cGMP‑ready cell expansion from development through commercialization
Anthropic’s agentic AI assistant connects with the Sapio Platform to enable data discovery, analysis, and action from a single prompt
Dr. Michael Kiebish of BPGbio shares insight into its AI-powered NAi Interrogative Biology Platform and discusses the growing importance of multiomic data
Test enables identification of patients whose tumors express PD-L1 for potential treatment with KEYTRUDA (pembrolizumab)
